Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
Sign Up to like & getrecommendations! Published in 2022 at "Disease Markers"
DOI: 10.1155/2022/4322404
Abstract: Background Apatinib is established to be the standard of care as third-line therapy for patients with previously treated advanced gastric cancer (GC). Programmed cell death protein 1 (PD-1) blockades also exhibited promising efficacy and safety… read more here.
Keywords: treated advanced; plus inhibitors; previously treated; apatinib plus ... See more keywords
Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of General Medicine"
DOI: 10.2147/ijgm.s379269
Abstract: Objective This study was to investigate the effectiveness and tolerability of anlotinib plus PD-1 inhibitors for patients with previously treated metastatic soft tissue sarcoma (STS). Methods Patients with previously treated metastatic STS who were administered… read more here.
Keywords: anlotinib plus; plus inhibitors; previously treated; patients previously ... See more keywords